22 Jul 2019,
  • HSI:
    28,542.59 -222.81 (-0.77%)
    10,841.29 -68.12 (-0.62%)
    36,760.92 -317.89 (-0.86%)
    96.14 0.16 (0.17%)
  • HSCEI:
    10,841.29 -68.12 (-0.62%)
    4,422.51 -32.05 (-0.72%)
    9,502.39 -67.89 (-0.71%)
    16,765.58 -160.13 (-0.95%)
  • Hang Seng Index
  • 28,542.59

  • -222.81 (-0.77%)
HSCI 10,841.3 -68.1
HKSPLC25 36,760.9 -317.9
HKSPGEM 96.1 0.2
HSCEI 10,841.3 -68.1
HSCCI 4,422.5 -32.1
HSFML25 9,502.4 -67.9
H-FIN 16,765.6 -160.1
Stay Connected With EQS TodayIR

Sanai Health Industry Group Company Limited (01889.HK)

Medical Supplies




2018 (AR)
2018 (IR)
2017 (AR)


  • Corporate Fac ...
  • Corporate Fac ...
  • Corporate Fac ...
The Group are a vertically integrated specialty pharmaceutical group focused on manufacturing, marketing, and selling its branded prescription and over-the-counter western pharmaceuticals and modern Chinese medicine products, including modern Chinese medicine injectibles, for the Chinese market. Its diversified product portfolio consists of 28 currently manufactured and marketed products that address significant medical needs in China in the therapeutic areas of respiratory, cardiovascular, gastrointestinal and infectious diseases and cancer.

The Group's principal products comprise a diversified set of 15 western pharmaceutical and 12 modern Chinese medicine products, of which 21 require a physician's prescription and the remaining 6 are over-the- counter drugs that can be obtained without a physician's prescription. These principal products form part of its diversified portfolio of 124 products, for which it have received approval and registration from the SFDA, possess the requisite technology and capacity to manufacture, and stand ready to manufacture and market at any time when the market demand for and the anticipated margin commanded by a particular product justify the manufacture and marketing of such product. Based on its market research, the Group choose to manufacture and sell products that anticipate will have strong market demand and that are likely to generate high margins. The Group currently choose to manufacture and sell 28 principal products because they generate higher margins than other products included in its portfolio......
+ More Company Profile

Mr. Lin Ou Wen - Chairman and CEO

Mr. Lin Ou Wen is the founding shareholder. Mr. Lin graduated from Fujian Normal University with a bachelor’s degree in physics in 1983. He is a senior economist. In 2000, he, together with other founding shareholders, established Fujian Sanai and has since then been appointed as the Chairman, Chief Executive Officer and executive Director. In January 2004, he established Fuzhou Sanai and has been appointed as the Chairman and Director. In March 2006, he further established Wuyi International Pharmaceutical Investment Company Limited (“Wuyi BVI”) and has since been appointed as the Chairman and Director. He has over 11 years of experience in the pharmaceutical industry. He is the younger brother of Mr. Lin Qing Ping.

Ms. Hung Hoi Lan - Executive Director

Ms. Hung Hoi Lan, aged 27, graduated from Sun Yat-Sen University with a bachelor’s degree in marketing in 2011. She later obtained a master degree of science in hospitality with tourism management from University of Birmingham in 2013. She started operating wine business ran by her family during her studies in the United Kingdom and has joined the business development department of Hilton Beijing since 2013. She was appointed as an executive Director with effect from 17 February 2017.

Mr. Zhang Jie - Independent Non-Executive Director

Mr. Zhang Jie, aged 32, obtained a bachelor’s degree in banking and international finance and a bachelor’s degree in commerce from Flinders University in Australia in 2010. In 2011, he obtained a master’s degree in business administration from Flinders University in Australia. He served as a senior auditor of an international audit services firm and is currently a senior consultant of a financial consultancy firm, focusing on enterprise consultation services. He is a CPA in Australia.

Mr. Zhang Xue Wen - Independent Non-Executive Director

Mr. Zhang Xue Wen, aged 44, graduated from Xiamen University with a bachelor’s degree in laws in 1994. He later obtained a master’s degree in laws from Xiamen University in 2004 and was awarded a doctorate degree in laws from Xiamen University in 2009. He was appointed as a judge of the Fuzhou Intermediate People’s Court in Fujian Province. He was also an associate researcher of the Faculty of Law of Fuzhou University. From November 2010 to April 2016, he engaged in postdoctoral research work at the Institute of Law of the Chinese Academy of Social Sciences. He currently serves as a researcher of the Institute of Law of the Fujian Academy of Social Science, a member of China Law Society, a council member of China Commercial Law Society and an arbitrator of Fuzhou Arbitration Commission. Mr. Zhang was on the list of 2013 Fujian Province Million Talents Project at provincial level, and has been awarded the Social Sciences Outstanding Achievement Award (Fujian Province) for several times. His published literary works and academic papers are also abundant.

Mr. Wu Cheng Han - Independent Non-Executive Director

Mr. Wu Cheng Han, aged 58, graduated from Guangzhou First Military Medical University in 1984 with a bachelor’s degree. He once served as the chief doctor in Neurology of Nanjing Military Zone Fuzhou General Hospital and a professor of Fujian University of Traditional Chinese Medicine. He is currently the chief doctor of the Second People’s Hospital of Fujian University of Traditional Chinese Medicine. He has been a standing committee member of the 11th session of Fujian Province Committee of the Chinese People’s Political Consultative Conference since 2013. He is also a member, deputy chairman, vice-president, standing committee member, senior advisor and so forth of various medical associations. Mr. Wu has been awarded the Outstanding Award for Academic Dissertation in Natural Science (Fujian Province) for several times. He is an editor for various medical journals and the inventor of various patents.

Mr. Chen Zhi Chuan - Chief Financial Officer

Mr. Chen Zhi Chuan, aged 50, is the Chief Financial Officer in charge of financial management. He graduated from Fuzhou University with a bachelor’s degree in Finance in 1988. He has over 12 years of experience in the pharmaceutical industry.

Mr. Cheng Shi De - Deputy General Manager

Mr. Cheng Shi De, aged 56, is the Deputy General Manager in charge of production. He graduated from Anhui Province Medical School with a bachelor’s degree in pharmacy in 1982. He is a senior engineer. He has over 30 years of experience in the pharmaceutical industry.

Ms. Yang Ai Min - Manager of Sales and Marketing

Ms. Yang Ai Min, aged 39, is the manager of Sales and Marketing. She graduated from Fujian Medical University with a bachelor’s degree in pharmacy in 1998. She has over 14 years of experience in the pharmaceutical industry.

Mr. Luk Ting Fung - Company Secretary

Mr. Luk Ting Fung, aged 32, is the Company Secretary. Mr. Luk graduated from The Chinese University of Hong Kong in 2007 with a bachelor’s degree of Science in Molecular Biotechnology. He has over 7 years of experience working in an international audit services firm and an investment bank, focusing on auditing and equity research and analysis. Mr. Luk also served as the senior finance manager in a chain department store listed on the Stock Exchange, responsible for accounting, financial management, tax planning and management, and business advisory services. He is a member of the Hong Kong Institute of Certified Public Accountants and has been registered as a Certified Public Accountant (Practising) in Hong Kong since 2015.

Professor Zhang Rongqing - Professor Zhang Rongqing

Professor Zhang, aged 60, was appointed as an independent non-executive director of the Company on 16 June 2017, and was a member of the Audit Committee, the Remuneration Committee and the Nomination Committee before the Re-designation. He graduated from Suzhou Medical College in 1982 with a Bachelor degree of medicine and received a PhD of animal physiology and biochemistry in Nanjing Agricultural University in 1993. Professor Zhang has worked as a professor in Tsinghua University since 1998, and he has been the associate dean of the School of Life Science in Tsinghua University. He is currently a director of the Institute of Biomedical Research in Yangtze Delta Region of Tsinghua University in ZheJiang, a deputy director of the Teaching Guidance Committee of the Ministry of Education about tertiary institutions’ biological technology and bio-engineering majors, a member of the 3rd and 4th Advisory Group of Experts of the “973” Plan in the field of agriculture, which is a key fundamental research development plan of the state. Professor Zhang has received many awards in science and technology, and has been the inventors of various patents. He is a well-known senior expert in the field of marine biochemistry & molecular biology, marine natural drug & gene engineering, and marine biological enzyme.

Audit Committee

Mr. Wang Zi Hao (Chairman)
Mr. Tu Fang Kui
Professor Zhang Rong Qing

Remuneration Committee

Mr. Wang Zi Hao (Chairman)
Mr. Chen Cheng Qing
Mr. Tu Fang Kui
Professor Zhang Rong Qing

Nomination Committee

Mr. Chen Cheng Qing (Chairman)
Mr. Tu Fang Kui
Mr. Wang Zi Hao
Professor Zhang Rong Qing

More details in relation to the Group's principal corporate governance practices can be found in our latest Corporate Governance Report 2015.
Memorandum and Articles of Association
Procedures for Shareholders to Propose a Person for Election as a Director


  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31      




Listed Date 01 Feb 2007

Address Unit 5, 7/F,
Nanyang Plaza,
57 Hung To Road,
Kwun Tong, Hong Kong

Telephone (852) 2827 6100

Facsimile (852) 2827 6099

Email wuyi.ir@wuyi-pharma.com.hk

No. of Click Rate